LONDON — The Danish agency Genmab stated Wednesday it will purchase ProfoundBio for $1.8 billion in money, the most recent in a string of 10-figure offers tied to the booming discipline of focused chemotherapies.
The acquisition will give Genmab ProfoundBio’s three drug candidates in trials, together with one referred to as Rina-S that’s in a Section 2 research for ovarian most cancers, in addition to preclinical applications. Rina-S can be being explored as a remedy in different strong tumors.
ProfoundBio is a privately held, Seattle-based biotech. It had most just lately introduced a $112 million Collection B spherical in February.